In 2018, genetic testing for Spinal Muscular Atrophy (SMA) by Multiplex Ligation-dependent Probe Amplification (MLPA) reported no pathogenic variants of microdeletions or microduplications in exons 7 and 8 of the SMN1 and SMN2 genes. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.